Modifier gene therapy – clinical development and manufacturing considerations
European Pharmaceutical Review
JUNE 13, 2024
Tell us about Ocugen’s lead programme, OCU400. Unlike conventional methods…modifier gene therapy…emphasises the importance of the broader biological system, potentially leading to more effective treatments.” What are the top three challenges associated with gene therapy manufacturing?
Let's personalize your content